February 12, 2026
The FDA's unusual refusal to review Moderna's mRNA flu vaccine sparks controversy over regulatory unpredictability and political influence.
February 5, 2026
GLP-1 wars heat up with divergent Lilly/Novo outlooks, Casgevy's rollout stalls on cell collection, & a psychedelic drug hits a WH roadblock.
February 3, 2026
Lipitor's journey from blockbuster cholesterol drug to medical controversy, questioning the true benefit versus risk for millions.
January 29, 2026
Huntington's advocate Lauren Holder details the community's fight for Unicure's gene therapy after a shocking FDA setback on its approval path.
January 22, 2026
A measles outbreak threatens the U.S.'s elimination status, while hospitals brace for Medicaid cuts and navigate a complex political landscape.
January 14, 2026
At JPM, Novo CEO talks obesity market strategy & DTC. VC Bob Nelsen covers biotech's future, China competition, and the impact of AI.
January 8, 2026
Big Pharma enters JPM week with a bullish outlook after navigating political threats, fueling M&A expectations amid cautious investor sentiment.
December 18, 2025
Biotech's 2025 review: The market is back, driven by M&A and fading macro risks. Experts discuss GLP-1 pricing, CEO awards, and a 2026 IPO surge.
December 11, 2025
ASH conference highlights, new obesity drug data, and a deep dive into the precarious future of American science under a new political landscape.
